Meeting
2019 ASCO Quality Care Symposium
Predictors of delays in initiation of oral tyrosine kinase inhibitors (TKIs) in EGFR and ALK positive advanced non-small cell lung cancer (NSCLC).
Authors
Bernardo H. L. Goulart
Fred Hutchinson Cancer Research Center, Seattle, WA
Bernardo H. L. Goulart, Shasank Chennupati, Kathryn Egan, Catherine R. Fedorenko, Scott David Ramsey
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cost, Value, and Policy; Health Equity and Disparities
Track
Cost, Value, and Policy,Health Care Access, Equity, and Disparities
Sub Track
Access to Care
Citation
J Clin Oncol 37, 2019 (suppl 27; abstr 134)
DOI
10.1200/JCO.2019.37.27_suppl.134
Abstract #
134
Poster Bd #
L3
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Development of clinically accessible nomograms to predict risk of brain metastases at baseline and follow-up in patients with non-small cell lung cancer.
First Author: Alireza Mansouri
Poster
2023 ASCO Annual Meeting
Circulating tumor DNA (ctDNA) dynamics and survival outcomes in patients (pts) with advanced non-small cell lung cancer (aNSCLC) and high (>50%) programmed cell death-ligand 1 (PD-L1) expression, randomized to cemiplimab (cemi) vs chemotherapy (chemo).
First Author: Natalie I Vokes
Poster
2023 ASCO Annual Meeting
Management of patients with ALK-positive advanced non-small cell lung cancer who received brain radiotherapy on study in the phase 3 CROWN trial.
First Author: Todd Michael Bauer
Poster
2023 ASCO Annual Meeting
Real-world testing and treatment patterns among patients with stage IV non-small cell lung cancer: A retrospective observational study.
First Author: Jeffrey A. Scott